Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality ...

Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.

Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course ...

Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to ...

First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers ...

The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company." ...

Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three ...

AI is evolving from interactive chats to automated workloads driven by agentic tools, compressing timelines and enabling faster outcomes. A new reference architecture running on the Dell Pro Max with ...

Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.